US pharmaceutical company Pfizer Inc (NYSE:PFE) has commenced a mid-to-late-stage study testing its investigational oral antiviral drug, PF-07321332, for the prevention of COVID-19 infection among those who have been exposed to the virus, Reuters news agency reported on Monday.
Pfizer said it would study the drug in up to 2,660 healthy adult participants aged 18 and older who live in the same household as an individual with a confirmed symptomatic COVID-19 infection.
The trial will reportedly test PF-07321332 with a low dose of ritonavir, an older medication widely used in combination treatments for HIV infection.
Pfizer had earlier said this month that it had started a mid-to-late-stage trial of PF-07321332 for the treatment of COVID-19 in non-hospitalised, symptomatic adult patients.
QOL Medical's Sucraid shows 81% effectiveness in Congenital Sucrase-Isomaltase Deficiency
Qlucore launches first CE-marked diagnostic test for paediatric leukaemia
Bruker demonstrates advancements in 4D-Proteomics at US HUPO
Mitem Pharma acquires Flisint rights from Sanofi to address rare infectious disease
Audientes partners with Audivista to expand hearing solutions in Middle East and North Africa
Benuvia Operations signs licensing deal with Avernus Pharma
Benuvia Operations signs licensing and supply agreements with Medra Brasil Medicamentos
Castle Biosciences to present data on Melanoma tests at ASDP Annual Meeting
Alchemy partners with PatchRx to improve HIV medication adherence